Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CVS HealthCVS +0.96%76 3-Year EBITDA Growth Rate is -6.00% as of Jun. 2026. GuruFocus rates CVS with a GF Score™ of 76/100 and a GF Value™ of $78.78 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 16 Healthcare Plans companies, CVS Health ranks worse than 56.25% on this metric.
During the past 12 months, CVS Health's average EBITDA Per Share Growth Rate was -7.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was -6.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -7.60% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was -0.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of CVS Health was 26.90% per year. The lowest was -14.80% per year. And the median was 7.80% per year.
CVS Health (NYSE:CVS) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
CVS Health 3-Year EBITDA Growth Rate Related Terms
CVS vs ELV, CI, HUM: 3-Year EBITDA Growth Rate Comparison
For the Healthcare Plans subindustry, CVS Health's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CVS Health 3-Year EBITDA Growth Rate vs Healthcare Plans Industry
For the Healthcare Plans industry and Healthcare sector, CVS Health's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where CVS Health's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -6.00% mean?
CVS Health (CVS) has a 3-Year EBITDA Growth Rate of -6.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for CVS Health and its competitors. According to the industry distribution chart, CVS Health ranks #9 out of 16 companies in the Healthcare Plans industry, placing it in the top 56.2%.
Is CVS Health's 3-Year EBITDA Growth Rate too high?
CVS Health's current 3-Year EBITDA Growth Rate is -6.00%. Based on the distribution chart, CVS Health ranks #9 out of 16 companies in the Healthcare Plans industry, which is below the industry midpoint. Overall, CVS Health has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CVS Health's 3-Year EBITDA Growth Rate compare to ELV and CI?
According to the Healthcare Plans industry distribution chart, CVS Health ranks #9 out of 16 companies for 3-Year EBITDA Growth Rate. This places CVS Health in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Plans company?
A good 3-Year EBITDA Growth Rate depends on the Healthcare Plans industry context. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for CVS Health and its competitors. CVS Health's current 3-Year EBITDA Growth Rate is -6.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CVS Health stock overvalued right now?
Based on GuruFocus' analysis, CVS Health (CVS) is currently considered Modestly Overvalued. The stock's GF Value™ is $78.78, compared to a current price of $94.91 — trading 20.5% above its estimated fair value. The current 3-Year EBITDA Growth Rate is -6.00%. CVS Health's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For CVS Health (CVS), the current 3-Year EBITDA Growth Rate is -6.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CVS Health (CVS) Overvalued in 2026?
Based on GuruFocus' analysis, CVS Health stock appears to be overvalued.
The current stock price of $94.91 is trading 20.5% above its estimated GF Value™ of $78.78.
GuruFocus considers CVS Health to be Modestly Overvalued.
Key valuation signals for CVS:
3-Year EBITDA Growth Rate: -6.00%
GF Value™: $78.78 vs. price of $94.91 (20.5% above fair value)
No single metric tells the full story. See the CVS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates around 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It operates a top-tier health insurer (acquired through Aetna) through which it serves about 27 million medical members. The acquisition of Oak Street Health added primary care services to the mix, which could have significant synergies with all existing business lines.
76GF Score
Get the complete analysis for CVS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVS has been successfully added to your 
